Ask about this productRelated genes to: ANXA3 antibody
- Gene:
- ANXA3 NIH gene
- Name:
- annexin A3
- Previous symbol:
- ANX3
- Synonyms:
- -
- Chromosome:
- 4q21.21
- Locus Type:
- gene with protein product
- Date approved:
- 1990-11-07
- Date modifiied:
- 2014-11-18
Related products to: ANXA3 antibody
Related articles to: ANXA3 antibody
- Sepsis is a major global health challenge characterized by a complex pathogenesis involving an early hyperinflammatory phase followed by a subsequent immunosuppressive state. Recent studies have revealed that dysregulation of fumarate metabolism plays a central role in immune dysregulation during sepsis, making related genes promising candidates as novel diagnostic biomarkers and therapeutic targets. - Source: PubMed
Publication date: 2026/05/11
Li MingZhao TingtingSun JingWang YunhuiShen Lin - Diabetic gastroparesis (DGP) is a common complication of diabetes mellitus, and its pathogenesis is complex and has not yet been fully elucidated. This study aims to investigate whether microtubule-associated protein 1 light chain 3 (LC3)-mediated autophagy promotes the progression of DGP by targeting sirtuin 1 (SIRT1). - Source: PubMed
Li PingZhang TianniHu JianzhuoWang Yipei - Acute pancreatitis (AP) is a severe inflammatory disorder in which pyroptosis-a pro-inflammatory form of programmed cell death-may contribute to pathogenesis. However, the complete transcriptional profile of pyroptosis-related genes (PRGs) in AP and their potential as diagnostic biomarkers remain underexplored. This study aimed to systematically characterize pyroptosis-associated transcriptional signatures and identify the reliable biomarkers for diagnostic purposes. Three transcriptomic datasets from murine AP models were integrated to identify pyroptosis-related differentially expressed genes (PRDEGs). Functional enrichment and immune cell infiltration analyses were conducted to elucidate the biological pathways and immune microenvironment alterations associated with these genes. mRNA-transcription factor (TF) and mRNA-microRNA (miRNA) regulatory networks were constructed to investigate underlying molecular interactions. Machine learning techniques, including support vector machine (SVM) and least absolute shrinkage and selection operator (LASSO), were applied for feature selection, leading to the identification of key diagnostic markers and the development of a logistic regression model. The regression model were then assessed using an independent cohort of human peripheral blood samples. Eleven PRDEGs were identified, with enrichment observed in processes such as cytoskeletal organization, cell-substrate adhesion, and critical inflammatory signaling pathways, including MAPK and NF-κB. Immune infiltration analysis revealed significant correlations between these PRDEGs and various immune cell subsets, particularly M1 macrophages, Treg cells, and monocytes. A four-gene diagnostic signature, comprising ANXA3, IQGAP1, RELA, and VTN, was established through SVM and LASSO analysis. In the independent human cohort, the fixed-coefficient four-gene model demonstrated reduced discrimination, which likely reflects interspecies and tissue-specific variations. However, after optimizing the model to exclude non-significant predictors, a refined two-gene signature (ANXA3 and IQGAP1) exhibited improved accuracy, with excellent calibration and clinical net benefit. This study offers a comprehensive transcriptomic analysis of the pyroptosis-mediated landscape and immune microenvironment in AP. An optimized two-gene signature, comprising ANXA3 and IQGAP1, was validated in a human cohort with superior accuracy, reflecting critical disruptions in inflammatory pathways and cytoskeletal organization. Notably, ANXA3 demonstrated potential for stratifying disease severity. Although these markers hold potential for molecular diagnosis, further prospective studies are essential to establish their clinical specificity and generalizability across diverse populations. - Source: PubMed
Publication date: 2026/04/17
Wang YutingLi JunYu ZhongsuLi ShuyuanChen YuxiaPan YunCheng LiangpingYu Guangyuan - Hepatocellular carcinoma (HCC) is one of the most lethal malignancies with limited treatment options. Lenvatinib is a first-line drug for advanced HCC. However, its effect on patient survival is limited and patients ultimately develop disease progression due to drug resistance. In this study, we established a lenvatinib-resistant orthotopic xenograft model and found a significant upregulation of ANXA3. Further researches revealed that ANXA3 facilitated lenvatinib resistance in vitro and in vivo. Mechanistically, ANXA3 activated the PI3K pathway and enhanced the transcription of PDGF-AA, thus promoting tumor angiogenesis. Besides, ANXA3 also promoted EMT and autophagy through the PI3K pathway. These three effects were comprehensively responsible for the roles of ANXA3 in facilitating lenvatinib resistance. What's more, the secreted PDGF-AA could in turn activate the PI3K pathway, thus forming a positive feedback loop, which could amplify the effects driven by ANXA3. Alpelisib is a PI3K inhibitor approved for breast cancer treatment by FDA. We demonstrated that Alpelisib may synergistically improve the antitumor effects of lenvatinib without increasing side effects. This study reports ANXA3 as a biomarker o predict poor prognosis and lenvatinib resistance in HCC. The combined use of Alpelisib and lenvatinib may serve as a potential therapeutic strategy for lenvatinib-resistant HCC. - Source: PubMed
Publication date: 2026/04/13
Zhu YingqinHuang YueSong MengjiaYang JieyingZhao JingjingTang YanOuyang DijunYang ChaopinChen YuanyuanWang QijingLi YongqiangHe JiaChen HaoXiang TongXia JianchuanPan Qiuzhong - Acute respiratory exacerbations in bronchiectasis are important as they impair quality of life and are associated with accelerated lung function decline. Yet, no validated methods exist to identify children at increased risk of exacerbations. We therefore determined if peripheral blood gene expression (GE) signatures can identify those at risk of an impending exacerbation. Thirty-one children with bronchiectasis had RNA extracted from peripheral blood collected whilst they were clinically stable, with 22 having an exacerbation during the next 3 months. Microarray assays using the HumanHT-12 v4.0 Expression BeadChip identified differentially expressed genes (p value ≤ 0.05, fold change > 1.5). The top targets were verified using real-time quantitative polymerase chain reaction (rt-qPCR) assays, and receiver operating characteristics and area under the curve (AUC) were assessed. Functional analysis of these genes was performed using Ingenuity Pathway Analysis. Overall, 647 entities were significantly dysregulated (p < 0.05) in the exacerbation group (n = 22), and pathway analysis identified neutrophil degranulation as the dominant affected pathway, which was also significantly inhibited (p < 0.001). Forty entities (32 genes) were associated with a future exacerbation (p ≤ 0.05, fold change ≥ 1.5) and six genes (ANXA3, ALAS2, DEFA1, ALPL, SNCA, PROK2) were verified using RT-qPCR (all p < 0.04) as the most discriminatory. DEFA1 and ANXA3 had the highest AUC (0.92, 95% confidence interval [CI] 0.82-1.00, and 0.87, 95% CI 0.73-1.00, respectively). We identified neutrophil-associated genes from peripheral blood that could be potential biomarkers for children with bronchiectasis at increased risk of exacerbations during the next 3 months. These GE signatures warrant further investigation and validation in larger, independent cohorts. KEY MESSAGES: Exacerbations in paediatric bronchiectasis are important. Peripheral blood gene expression may help identify children at risk of exacerbations. Six neutrophil-associated genes were associated with a future exacerbation. Identifying predictive gene expression signatures warrants further investigation. - Source: PubMed
Publication date: 2026/04/01
O'Farrell Hannah EGoyal VikasChang Anne BGrimwood KeithCheng MichaelYerkovich Stephanie TBaines Katherine J